Systemic Biologic Therapies for Psoriasis

Skill level: Intermediate

Estimated time to complete activity: 45 min

Release date: October 08, 2018

Expiration date: October 08, 2020

English

American Medical Association(AMA), California Board of Registered Nursing(CBRN)

This activity is part of a 14-course series designed to equip licensed practitioners from medical, nursing, and related disciplines with a multidisciplinary approach to managing patients with psoriasis.

5. Systemic Biologic Therapies for Psoriasis

Biologics have swept the field of medicine over the last decade and now a wide range of biologic agents are approved for psoriasis. These powerful agents can be life changing for patients with psoriasis but are not for everyone. This activity will review the science behind the different classes of biologics in the treatment of psoriasis.

Educational Objectives

After completing this activity, participants will able to:

• Summarize systemic biologic agents available for psoriasis treatments
• Contrast the cellular pathways of phosphodiesterase, TNF-alpha, IL 12/IL23, IL17, and IL23 and their roles in psoriasis therapy and side effects

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Faculty	Reported Financial Relationship
Jeffrey Crowley, MD	Investigator/Consultant/Speaker: AbbVie, Celgene, Janssen, Lilly, Novartis, Regeneron, Sanofi-Aventis, Sun Pharma, UCB Investigator: Merck, Pfizer, MC2 Therapeutics, Sandoz, Verrica Pharmaceuticals